Toxicity of MRI and CT contrast agents

@article{Hasebroock2009ToxicityOM,
  title={Toxicity of MRI and CT contrast agents},
  author={Kendra M. Hasebroock and Natalie J. Serkova},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2009},
  volume={5},
  pages={403 - 416}
}
Anatomical and physiological imaging using CT and MRI are playing a critical role in patients’ diagnosis, disease characterization and treatment planning. CT- and MRI-based protocols increasingly require an injection of iodinated CT and gadolinium (Gd)-based MRI contrast media. Although routinely used in clinical practice, iodinated and to a less extent Gd-based contrast media possess side effects: life-threatening contrast-induced nephropathy (CIN) is associated with CT and nephrogenic… 

X-ray-computed tomography contrast agents.

The strong relationship between absorption and atomic number is of significant importance in clinical applications and the Z4 factor allows for contrast levels of several orders of magnitude between different tissues and types of contrast agents.

Non-contrast-enhanced magnetic resonance imaging can be used to assess renal cortical and medullary volumes—A validation study

The proposed widely available non-contrast-enhanced MRI method can quantify cortical and medullary renal volumes and can be directly implemented clinically.

Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.

An association with GBCAs in the development of NSF is suggested in the setting of renal insufficiency, but other factors seem to play a role.

Findings in whole body MRI and conventional imaging in patients with fever of unknown origin-a retrospective study

Wb-MRI appears to be of value in the evaluation of FUO patients, allowing for optimized treatment by increasing diagnostic certainty and due to its lack of nephrotoxicity and ionizing radiation it may be preferred over standard imaging techniques and PET-CT in the future.

Biocompatible carbonized iodine-doped dots for contrast-enhanced CT imaging

The remarkable CT contrast enhancement and biocompatibility of IDC can be used as an effective CT contrast agent for the diagnosis of various diseases compared with conventional CT contrast agents.

The diagnostic performance of contrast-enhanced CT versus extracellular contrast agent-enhanced MRI in detecting hepatocellular carcinoma: direct comparison and a meta-analysis

ECA-MRI provided higher sensitivity and accuracy than contrast-enhanced CT in detecting HCC, especially lesions size < 20 mm.

Iron Oxide Nanoparticles as T1 Contrast Agents for Magnetic Resonance Imaging: Fundamentals, Challenges, Applications, and Prospectives

The fundamental principles of MRI contrast agents are discussed, and the current status ofMRI contrast agents is reviewed with a focus on the advantages and limitations of current T1 contrast agents and the potential of IONPs to serve as safe and improved alternative to gadolinium‐based chelates.

Nephrotoxic Polypharmacy and Risk of Contrast Medium-Induced Nephropathy in Hospitalized Patients Undergoing Contrast-Enhanced CT.

Among the known risk factors, such as preexisting renal disease, high serum creatinine level, and low hemoglobin level, a statistically significant association was identified between CM-induced nephropathy and concurrent receipt of four nephrotoxic medications.

The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure.

The incidence of CIN in patients with diabetes and chronic kidney disease receiving IV contrast medium was not significantly different after CT using iopamidol 370 or iodixanol 320.

Application of dynamic contrast enhanced ultrasound in distinguishing focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma.

DCE-US with quantitative analysis has the potential to make preoperative differential diagnosis between focal-type AIP and PDAC non-invasively.
...

References

SHOWING 1-10 OF 104 REFERENCES

Imaging patients with chronic kidney disease: CIN or NSF?

In order to optimise patient outcomes, imaging of patients with CKD requires an understanding of the risk factors for both CIN and NSF.

Editorial: Gadolinium Use in Patients with Kidney Disease: A Cause for Concern

Caution should be exercised when utilizing gadolinium as a contrast agent in patients with advanced CKD or ESRD, especially those with diabetic nephropathy.

Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?

A patient with reduced renal function faces the unpleasant choice of risking contrast medium-induced nephropathy (CIN) after administration of iodine-based CM or NSF after exposure to gadolinium-basedCM, and new knowledge has complicated work in the imaging department.

New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice.

Extracellular gadolinium-based contrast media: an overview.

Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates.

Gadolinium-based contrast media are safe and well tolerated by the vast majority of patients and the adverse reaction rate and the incidence of severe anaphylactoid reaction concur with those reported in the literature.

Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents

The situation regarding gadolinium based contrast agent and the severe delayed reaction to some of these agents is reviewed and the fear of nephrogenic systemic fibrosis should not lead to a denial of a well indicated enhanced magnetic resonance imaging examination.

Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.

An association with GBCAs in the development of NSF is suggested in the setting of renal insufficiency, but other factors seem to play a role.

Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT – A pooled analysis of two randomized trials

Following the IV administration of nonionic contrast agents in patients with moderate-to-severe renal insufficiency, the risk of significant CIN seems to be low and differences in osmolality between these LOCM and iodixanol do not play a role in the genesis of CIN.

Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

It is shown that gadodiamide plays a causative role in nephrogenic systemic fibrosis, and seven patients became severely disabled, and one died 21 mo after exposure.
...